Published by Alexander Bueso on 30th August 2022
(Sharecast News) - Clinical trial results showed that AstraZeneca's Farxiga treatment against Type II diabetes significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction.